41147-82-4

Basic information

• Product Name: 4-Bromo-beta-hydroxyphenethylamine
• Synonyms: 2-Amino-1-(4-bromophenyl)ethan-1-ol;4-Bromo-beta-hydroxyphenethylamine;2-AMINO-1-(4-BROMOPHENYL)ETHANOL;UKRORGSYN-BB BBV-182843;2-AMino-1-(4-broMophenyl)ethanol HCl;2-Amino-1-(4-bromophenyl)ethan-1-ol, 4-Bromo-beta-hydroxyphenethylamine;alpha-(Aminomethyl)-4-bromobenzyl alcohol
• CAS NO: 41147-82-4
• Molecular Formula: C₈H₁₀BrNO
• Molecular Weight: 216.08
• Mol File: 41147-82-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 111-113°
• Boiling Point: 341.6±27.0 °C(Predicted)
• Appearance: /
• Density: 1.539±0.06 g/cm3(Predicted)
• PKA: 11.83±0.35(Predicted)
• CAS DataBase Reference: 4-Bromo-beta-hydroxyphenethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-beta-hydroxyphenethylamine(41147-82-4)
• EPA Substance Registry System: 4-Bromo-beta-hydroxyphenethylamine(41147-82-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 41147-82-4(Hazardous Substances Data)

Usage

General Description

4-Bromo-beta-hydroxyphenethylamine, also known as DOB or 2,5-Dimethoxy-4-bromophenethylamine, is a powerful synthetic psychedelic drug that affects serotonin receptors in the brain. It was first synthesized in the 1960s by chemists Shulgin and Nichols, and it is chemically similar to the compounds mescaline and amphetamine. The chemical formula of DOB is C10H14BrNO2 and it has structural similarities to other psychoactive compounds, namely amphetamines and phenethylamines. The effects of the drug can last up to 24 hours and can include intense visualizations, euphoria, and potentially dangerous physical effects such as increased heart rate and dehydration. It is categorized as a Schedule I drug in the United States, making it illegal to manufacture, distribute, or possess.

Upstream product

• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 32017-76-8 (+/-)-2-(4-bromophenyl)oxirane 
• 7644-04-4 4-bromophenacylamine 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 
• 58289-69-3 2-(4-bromophenyl)-2-hydroxyacetonitrile 
• 49615-87-4 2-(4-bromophenyl)-2-oxoacetaldehyde oxime 
• 71559-14-3 2-azido-1-(4-bromophenyl)ethanone 
• 99-73-0 para-bromophenacyl bromide 

Downstream Products

• 10145-39-8 5-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine 
• 137935-16-1 1-[2-(4-Bromo-phenyl)-2-hydroxy-ethyl]-3-cyclohexyl-thiourea 
• 479493-66-8 2-[2-(4-bromophenyl)-2-hydroxyethylamino]-4,6-dichloropyrimidine 
• 479493-65-7 6-[2-(4-bromophenyl)-2-hydroxyethylamino]-2,4-dichloropyrimidine 
• 137935-23-0 [5-(4-Bromo-phenyl)-4,5-dihydro-thiazol-2-yl]-cyclohexyl-amine 
• 1368418-27-2 6-(4-bromophenyl)morpholin-3-one 
• 1467061-26-2 6-chloro-5-[4-(5-oxomorpholin-2-yl)phenyl]-1H-indole-3-carbaldehyde 
• 1467058-77-0 6-chloro-5-[4-(5-oxomorpholin-2-yl)phenyl]-1H-indole-3-carboxylic acid 
• 1467061-25-1 N-(2-(4-bromophenyl)-2-hydroxyethyl)-2-chloroacetamide 
• 1131220-82-0 tert-butyl 2-(4-bromophenyl)morpholine-4-carboxylate 
• 83555-73-1 (RS)-2-(4-bromophenyl)morpholine 
• 913181-90-5 tert-butyl (2-(4-bromophenyl)-2-hydroxyethyl)carbamate 

Relevant articles and documents

Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists

A new series of morpholine derivatives has been identified as selective DA D3 receptor antagonists; their in vitro profile and pharmacokinetic data are provided.

Regio-selective synthesis of 1,2-aminoalcohols from epoxides and chlorohydrins

A simple and efficient procedure for the regio-selective synthesis of 1,2-aminoalcohols from terminal epoxides and chlorohydrins by using NaHMDS as the source of amine is reported. The wider scope and utility of this method is demonstrated.

OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

The present invention is directed to compounds of Formula (I): Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.